Donate Now

Eliminating Anti-Rejection Drugs

Eliminating anti-rejection drugs for kidney transplant recipients

Northwestern University
Chicago, IL Dr. Joseph Leventhal

At Northwestern University in Chicago, the National Stem Cell Foundation partnered with the U.S. Department of Defense to help fund a collaboration between the Institute for Cellular Therapeutics (ICT) at the University of Louisville and Dr. Joseph Leventhal, Professor of Surgery in the Division of Organ Transplantation at Northwestern University Medical School and Director of the Living Donor Renal Transplant Program at Northwestern Memorial Hospital.

This collaboration is used stem cells from a kidney donor to eliminate the need for anti-rejection drugs following a kidney transplant.


Dr. Joseph Leventhal is Professor of Surgery and Director of Kidney and Pancreas Transplantation at Northwestern University Feinberg School of Medicine. He received his M.D. from SUNY Downstate Health Sciences University. He completed his surgical training and received his Ph.D. in Surgical Science from the University of Minnesota.

He is a leader in the field of regulatory T cells, focusing his research on the biology of regulatory T cells and their potential for the control of the immune system after organ transplantation.

Dr. Leventhal is the co-founder of TRACT Therapeutics.